PhaseBio Pharmaceuticals Inc
PHAS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PHAS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2022.
Tracking 2 pipeline candidates for PhaseBio Pharmaceuticals Inc.
Run PhaseBio Pharmaceuticals Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PhaseBio Pharmaceuticals Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
2.6 months
OCF -$10M · Net income -$17M
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is PhaseBio Pharmaceuticals Inc's lead drug candidate?
PhaseBio Pharmaceuticals Inc's most advanced tracked candidate is bentracimab (Phase 3) for Reversal of antiplatelet activity of ticagrelor in patients with uncontrolled major or life-threatening bleeding or requiring urgent surgery or an invasive procedure.
What therapeutic areas does PhaseBio Pharmaceuticals Inc focus on?
PhaseBio Pharmaceuticals Inc develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.